These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 7831675)

  • 1. Repeated release of the tissue factor pathway inhibitor.
    Ariëns RA; Faioni EM; Mannucci PM
    Thromb Haemost; 1994 Aug; 72(2):327-8. PubMed ID: 7831675
    [No Abstract]   [Full Text] [Related]  

  • 2. Heparin-releasable and platelet pools of tissue factor pathway inhibitor in rabbits.
    Warn-Cramer BJ; Maki SL; Rapaport SI
    Thromb Haemost; 1993 Mar; 69(3):221-6. PubMed ID: 8470044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue factor pathway inhibitor (TFPI).
    Rucińska M; Gacko M; Skrzydlewski Z
    Rocz Akad Med Bialymst; 1997; 42 Suppl 1():118-22. PubMed ID: 9337530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fucoidan, as heparin, induces tissue factor pathway inhibitor release from cultured human endothelial cells.
    Giraux JL; Tapon-Bretaudière J; Matou S; Fischer AM
    Thromb Haemost; 1998 Oct; 80(4):692-5. PubMed ID: 9798992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Administration of nonanticoagulant heparin inhibits the loss of glycosaminoglycans from xenogeneic cardiac grafts and prolongs graft survival.
    Stevens RB; Wang YL; Kaji H; Lloveras J; Dalmasso A; Bach FH; Rubinstein P; Sutherland DE; Platt JL
    Transplant Proc; 1993 Feb; 25(1 Pt 1):382. PubMed ID: 8438344
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of heparin removal in vitro on the activity of tissue factor pathway inhibitor.
    Mukherjee M
    Br J Haematol; 2000 Nov; 111(2):714-5. PubMed ID: 11189101
    [No Abstract]   [Full Text] [Related]  

  • 7. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man.
    Hansen JB; Sandset PM; Huseby KR; Huseby NE; Nordøy A
    Thromb Haemost; 1996 Nov; 76(5):703-9. PubMed ID: 8950777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Release of endothelium-associated proteins into blood by injection of heparin in normal subjects and in patients with Type 1 diabetes.
    Myrup B; Yokoyama H; Kristiansen OP; Østergaard PB; Olivecrona T
    Diabet Med; 2004 Oct; 21(10):1135-40. PubMed ID: 15384962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel vascular endothelial growth factor heparin-binding domain substructure binds to glycosaminoglycans in vivo and localizes to tumor microvascular endothelium.
    El-Sheikh A; Liu C; Huang H; Edgington TS
    Cancer Res; 2002 Dec; 62(23):7118-23. PubMed ID: 12460934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of unfractionated heparin and a low molecular weight heparin (enoxaparin) on coagulant activity of cultured human endothelial cells.
    Martinez-Sales V; Vila V; Réganon E; Oms JG; Aznar J
    Haematologica; 2003 Jun; 88(6):694-9. PubMed ID: 12801846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor.
    Zhang J; Piro O; Lu L; Broze GJ
    Circulation; 2003 Aug; 108(5):623-7. PubMed ID: 12835228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bemiparin and fluid flow modulate the expression, activity and release of tissue factor pathway inhibitor in human endothelial cells in vitro.
    Westmuckett AD; Kakkar VV; Hamuro T; Lupu F; Lupu C
    Thromb Haemost; 2001 Dec; 86(6):1547-54. PubMed ID: 11776326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of native VLDL on tissue factor pathway inhibitor in endothelial cells and interactions between TFPI and lipoprotein lipase.
    Brodin E; Iversen N; Hansen JB
    J Lab Clin Med; 2006 Apr; 147(4):167-73. PubMed ID: 16581344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin stimulates the release of glycosaminoglycans from cultured human endothelial cells.
    Kaji T; Sakuragawa N
    Thromb Res; 1990 Jan; 57(1):163-8. PubMed ID: 2300921
    [No Abstract]   [Full Text] [Related]  

  • 15. Heparin enhances endothelial cell von Willebrand factor content by growth factor dependent mechanisms.
    Tannenbaum SH; Chao ES; Gralnick HR
    Thromb Haemost; 1994 Nov; 72(5):770-6. PubMed ID: 7900084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.
    Théoleyre S; Kwan Tat S; Vusio P; Blanchard F; Gallagher J; Ricard-Blum S; Fortun Y; Padrines M; Rédini F; Heymann D
    Biochem Biophys Res Commun; 2006 Aug; 347(2):460-7. PubMed ID: 16828054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Further insight into the heparin-releasable and glycosylphosphatidylinositol-lipid--anchored forms of tissue factor pathway inhibitor.
    Ellery PE; Hardy K; Oostryck R; Adams MJ
    Clin Appl Thromb Hemost; 2008 Jul; 14(3):267-78. PubMed ID: 18160611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Organ glycosaminoglycan distribution after intravenous and oral administration in rats.
    Marchi E; Barbanti M; Milani R; Breccia A; Fini A; Gattavecchia E
    Semin Thromb Hemost; 1994; 20(3):297-300. PubMed ID: 7824965
    [No Abstract]   [Full Text] [Related]  

  • 19. Endostatin competes with bFGF for binding to heparin-like glycosaminoglycans.
    Reis RC; Schuppan D; Barreto AC; Bauer M; Bork JP; Hassler G; Coelho-Sampaio T
    Biochem Biophys Res Commun; 2005 Aug; 333(3):976-83. PubMed ID: 15985216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor Xa enhances the binding of tissue factor pathway inhibitor to acidic phospholipids.
    Valentin S; Schousboe I
    Thromb Haemost; 1996 May; 75(5):796-800. PubMed ID: 8725726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.